Inactive

This is a Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding the availability and capabil... This is a Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding the availability and capability of all qualified sources to perform a potential requirement. For equipment/supply requirements, responses must include: (1) the place of manufacturing (i.e. address if supply/equipment is a domestic end product and include country of manufacture), as well as (2) the size status of the manufacturer under the applicable NAICS code (i.e. address Non-Manufacturer Rule). This notice is issued to help determine the availability of qualified companies technically capable of meeting the Government requirement and to determine the method of acquisition. It is not to be construed as a commitment by the Government to issue a solicitation or ultimately award a contract. Responses will not be considered as proposals or quotes. No award will be made as a result of this notice. The Government will NOT be responsible for any costs incurred by the respondents to this notice. This notice is strictly for research and information purposes only. Background: The Functional Genomics group of the National Center for Advancing Translational Sciences (NCATS), Division of Preclinical Innovation (DPI) requires a kit named “Human Apolipoprotein B kit". This type of assay is an ApoB assay featuring a streamlined protocol with only one incubation step following the sample/calibrator and antibody conjugates dispensing. The antibodies labelled with HTRF donor and acceptor may be pre-mixed and added in a single dispensing step to further streamline the assay procedure. This protocol requires a single 3-hour incubation period at RT. The group uses these kits to screen siRNA libraries for the collaborations they have with other institutes. This type of assay is homogenous which can be miniaturized into 384 well plate format and thus ideally suited for high throughput applications. Purpose and Objectives: The purpose of this acquisition is to acquire four (4) units of Perkin Elmer’s HTRF Human Apolipoprotein B kit or Equal that meet all salient characteristics. The salient physical, functional, or performance characteristics that “equal” products must meet are specified in the purchase description below. Purchase Description: Perkin Elmer’s HTRF Human Apolipoprotein B kit or Equal Salient characteristics: The following salient characteristics are necessary for the requested supplies: 1) Combination of homogenous, mix-and-read assay formats and Fluorescence Energy Transfer (FRET) 2) Does not require pre-coating the plate or plate washing like conventional ELISA assays 3) Validated to detect the lowest concentration of cAMP(IC50) 4) Validated with Gs agonist and antagonist compounds Delivery Date: Within 60 days after receipt of order Capability statement /information sought: Respondents must provide clear and convincing documentation of their capability of providing the equipment specified in this notice. The respondent must also provide their UEI number, organization name, address, point of contact, and size and type of business (e.g., 8(a), HubZone, etc., pursuant to the applicable NAICS code and any other information that may be helpful in developing or finalizing the acquisition requirements. One (1) copy of the response is required and must be in Microsoft Word or Adobe PDF format using 11-point or 12-point font, 8-1/2” x 11” paper size, with 1” top, bottom, left and right margins, and with single or double spacing. The information submitted must be in an outline format that addresses each of the elements of the service requirement and in the capability statement /information sought paragraphs stated herein. The response must include the respondents’ technical and administrative points of contact, including names, titles, addresses, telephone numbers, and e-mail addresses. All responses to this notice must be submitted electronically to the Contract Specialist. Facsimile responses are NOT accepted. The response must be submitted to Sarah Adan, at e-mail address sarah.adan@nih.gov with the subject line NCATS-22-005110SS. The response must be received on or before June 15, 2022, 12:00 pm, Eastern Time.